Penny stocks are valued at $5.00 or less, and they definitely divide opinion among investors. Some love them for their low share price and the possibility for huge returns, while others loathe the level of risk and uncertainty involved. However, if you fall into the category of the former, we’ve got just the stocks for you. Let’s take a look at TherapeuticsMD and Bellicum Pharmaceuticals.
TherapeuticsMD (NASDAQ:TXMD)
TXMD is a Florida-based biopharma firm that focuses on advancing the health of women and championing awareness of female health care issues. TXMD has soared over 20% today after it was revealed that JP Morgan (NYSE:JPM) had taken a substantial position in the firm, owning about 19.7 million shares or 7% of the outstanding shares. The company has three approved products already on the market, which management believes can generate US$2 billion in combined sales, and JP Morgan clearly believes in this penny stock.
TXMD stock is currently trading for $2.81.
>> GNPX Stock Quadruples on FDA Fast Track Status for Oncoprex Therapy
Bellicum Pharmaceuticals Inc (NYSE:BLCM)
Bellicum is a Houston-based pharmaceutical that focuses on the treatment of novel cellular immunotherapies for certain cancers, and orphan inherited blood disorders. This penny stock has been building momentum over the last few weeks as the company prepares to present new data for its BPX-501 therapy at the ASCO 2020 Gastrointestinal Cancers Symposium on Friday. Momentum ahead of a data release is a common trend among pharma penny stocks, and optimism is clearly high for this one, with BLCM stock going from $0.80 in mid-December to $2.17 today.
In a double whammy for this penny stock, BLCM shares gained 11% in premarket trading today after it was announced that it had sold its 60,000 square-foot Houston manufacturing plant to The University of Texas MD Anderson Cancer Center for US$15 million. While MD Anderson will be allowed to use the plant for its own purposes, it will also continue to manufacture Bellicum’s GoCAR treatment and other cellular therapy programs for clinical trials and potentially early commercial supply.
If you’re an investor who enjoys healthcare stocks, you might want to check out our three to watch for 2020. That’s our pick of penny stocks for this Tuesday; have any more caught your eye recently?
Featured Image: DepositPhotos © Frankljunior
